Medincell
Medincell, a pioneering biopharmaceutical company headquartered in France, focuses on the development of innovative long-acting injectable therapies. Founded in 2000, the company has made significant strides in the industry, particularly in the fields of mental health and chronic diseases. Medincell's proprietary technology platform, which enables the sustained release of active pharmaceutical ingredients, sets it apart from competitors. With a strong presence in Europe and expanding operations globally, Medincell is committed to addressing unmet medical needs through its core products, including its lead candidate for the treatment of schizophrenia. The company has garnered recognition for its unique approach to drug delivery, positioning itself as a leader in the biopharmaceutical sector. Medincell continues to advance its mission of improving patient outcomes through innovative therapeutic solutions.
DitchCarbon Score
How does Medincell's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medincell's score of 57 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medincell's reported carbon emissions
In 2023, Medincell reported total carbon emissions of approximately 1,000,000 kg CO2e, comprising 776 kg CO2e from Scope 1 and 40,820 kg CO2e from Scope 2 emissions. The majority of their emissions, about 951,404 kg CO2e, originated from Scope 3, which includes significant contributions from purchased goods and services (5,120,280 kg CO2e) and business travel (248,460 kg CO2e). In 2022, the company’s total emissions were approximately 6,660,740 kg CO2e, with Scope 2 emissions at 12,860 kg CO2e and Scope 3 emissions accounting for about 6,647,870 kg CO2e. This indicates a notable increase in emissions from 2022 to 2023, primarily driven by Scope 3 activities. Medincell has not disclosed specific reduction targets or initiatives as part of their climate commitments. However, they continue to monitor and report their emissions across all relevant scopes, demonstrating a commitment to transparency in their environmental impact. The company is headquartered in France and operates within the global pharmaceutical industry, which is increasingly focused on sustainability and reducing carbon footprints.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | 000 | 000 |
| Scope 2 | 7,640 | 0,000 | 0,000 | 00,000 | 00,000 | 00,000 |
| Scope 3 | - | 00,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medincell is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
